Phase 2 Trial of CMK389 Recruiting Adults With Pulmonary Sarcoidosis

Phase 2 Trial of CMK389 Recruiting Adults With Pulmonary Sarcoidosis

312527

Phase 2 Trial of CMK389 Recruiting Adults With Pulmonary Sarcoidosis

A Phase 2 clinical trial is recruiting adults with chronic pulmonary sarcoidosis to investigate the safety and therapeutic potential of CMK389 in improving lung function. CMK389 is an investigational therapy, developed by Novartis, for the treatment of pulmonary sarcoidosis and atopic dermatitis. It was designed to inhibit interleukin 18, a signaling molecule known to play a role in lung sarcoidosis progression. The proof-of-concept trial (NCT04064242), done in collaboration with the Foundation for Sarcoidosis Research, is currently…

You must be logged in to read/download the full post.